NewAmsterdam Pharma Company N.V. (NAMS) — Analyst outlook / Analyst consensus target is. Based on 10 analyst ratings, the consensus is bullish — 9 Buy, 1 Hold.
The consensus price target is $47.20 (low: $37.00, high: $55.00), representing an upside of 37% from the current price $34.44.
Analysts estimate Earnings Per Share (EPS) of $-2.03 and revenue of $0.03B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-2.56 vs est $-2.03 (missed -26%). 2025: actual $-1.75 vs est $-1.67 (missed -5.1%). Analyst accuracy: 87%.
NAMS Stock — 12-Month Price Forecast
$47.20
▲ +37.05% Upside
Average Price Target
Based on 10 Wall Street analysts offering 12-month price targets for NewAmsterdam Pharma Company N.V., the average price target is $47.20, with a high forecast of $55.00, and a low forecast of $37.00.
The average price target represents a +37.05% change from the last price of $34.44.
Highest Price Target
$55.00
Average Price Target
$47.20
Lowest Price Target
$37.00
NAMS Analyst Ratings
Buy
Based on 10 analysts giving stock ratings to NewAmsterdam Pharma Company N.V. in the past 3 months
EPS Estimates — NAMS
87%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$2.56
vs Est –$2.03
▼ 20.7% off
2025
Actual –$1.75
vs Est –$1.67
▼ 4.9% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — NAMS
84%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.046B
vs Est $0.034B
▲ 25.9% off
2025
Actual $0.023B
vs Est $0.024B
▼ 6.6% off
Revenue Trend
Revenue has declined over the period shown. Analysts forecast significant revenue growth ahead.
